Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=yhct21 HIV Research & Clinical Practice ISSN: 2578-7489 (Print) 2578-7470 (Online) Journal homepage: https://www.tandfonline.com/loi/yhct21 Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy S. Bowler, C. Siriwardhana, B. I. Mitchell., M. l. d’Antoni, D. Ogata-Arakaki, S. Souza., R. Yee., L. M. A. Gangcuangco, D. C. Chow., L. C. Ndhlovu. & C. Shikuma To cite this article: S. Bowler, C. Siriwardhana, B. I. Mitchell., M. l. d’Antoni, D. Ogata-Arakaki, S. Souza., R. Yee., L. M. A. Gangcuangco, D. C. Chow., L. C. Ndhlovu. & C. Shikuma (2020): Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy, HIV Research & Clinical Practice, DOI: 10.1080/25787489.2020.1719319 To link to this article: https://doi.org/10.1080/25787489.2020.1719319 Published online: 04 Feb 2020. Submit your article to this journal View related articles View Crossmark data